TRIM21 and systemic sclerosis: In anti-Ro52-positive SSc patients, the clinical and immunological characteristics between anti-Ro52+/anti-Ro60– and anti-Ro52+/anti-Ro60+ SSc patients did not reveal any statistically significant differences (Supplementary Table 2).